More Transparency In Medical Product Prices Discussed At Event 24/02/2017 by Catherine Saez, Intellectual Property Watch 2 Comments The lack of access to medical products has spread from being a developing country problem to a global one as prices are now too high even for developed country patients and health systems for some medicines. An event at the Graduate Institute Global Public Health Centre yesterday was an opportunity to explore these issues.
German-Backed Report Lays Out Strategy For R&D Into New Antibiotics 23/02/2017 by Catherine Saez, Intellectual Property Watch 1 Comment In the face of the lack of attractiveness of investing in research for new antibiotics for the pharmaceutical industry, and the general lack of funding for research and development for novel antibiotics, a new report commissioned by the German Federal Ministry of Health calls for countries to take action. In particular, the report proposes a global union for research and development, a global research fund, and a global launch reward. And access and pricing are key components of the strategy, it says.
Side Event On UN High-Level Panel On Access To Medicines Next Week At WTO 23/02/2017 by Intellectual Property Watch 1 Comment As the World Trade Organization intellectual property committee meeting next week is expected to discuss the report of the United Nations Secretary General’s High-Level Panel on Access to Medicines next week, a group of developing countries is convening a side event to engage in discussion with members of the panel. The report included several direct recommendations to WTO members.
Momentum-Building: An Interview With Ruth Dreifuss On High-Level Panel On Access To Medicines 22/02/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment Former Swiss President Ruth Dreifuss, co-chair of the United Nations Secretary General’s High-Level Panel on Access to Medicines, participated in a Geneva event on rare diseases earlier this month. She agreed to answer Intellectual Property Watch’s Catherine Saez about the High-Level Panel report, in particular how it was received by the international community, her take on criticisms that have been voiced, and the importance that the report be discussed at the international level such as the World Health Assembly.
TRIPS Council To Consider The Two Sides Of IP – Innovation Booster And Barrier 21/02/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment The role of intellectual property in innovation is expected to be considered through different lenses at the upcoming meeting of the World Trade Organization committee on intellectual property. A group of developed countries have proposed an agenda item on inclusive innovation in micro, small and medium-sized enterprises, while discussions are expected on the report of the United Nations Secretary General’s High-Level Panel on Access to Medicines, and a side event featuring High-Level Panel members has been convened by a group of developing countries. Electronic commerce, and in particular copyright issues and electronic signatures are also on the agenda next week.
European Commission Public Consultation On Plan To Fight Antimicrobial Resistance 21/02/2017 by Intellectual Property Watch 2 Comments The European Commission has launched a call for comments on its proposed plan to help EU members fight antimicrobial resistance.
Health Security An Integral Part Of International Security, Experts Warn 20/02/2017 by Monika Ermert for Intellectual Property Watch Leave a Comment Microsoft founder and Bill & Melinda Gates Foundation Co-Chair Bill Gates called on governments gathered at the annual Munich Security Conference this week to not “ignore the link between health security and international security.”
BIO Investor Conference: New Technologies, Old Pricing Systems, And Insurance Payers In The US 20/02/2017 by Kim Treanor for Intellectual Property Watch 1 Comment NEW YORK — At a recent biotechnology investors event in the United States, the prospect of repeal or redesign of the Affordable Care Act, the president’s recent remarks on the prospect of Medicare negotiating prices directly with pharmaceutical corporations, and the public debate surrounding high priced medicines, meant few panels were immune from questions of affordability, access and payment.
New Gene-Editing Technology Whets Appetites In Health, Food Industry, Fuels Patent Fights 16/02/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment A new discovery allowing easier and swifter genome editing, considered by some as a major game changer in the field of biology, is opening doors to new technological wonders in many areas, such as medicines and agriculture. Yesterday, the United States Patent and Trademark Office issued a ruling on a case where two US university laboratories both claimed the invention of a genome editing technique. The USPTO decided that the two universities had made distinct discoveries. In Europe, patents from both universities on the technology are also challenged at the European Patent Office.
Special Report: WHO Board Sets Review Of 10-Year Effort To Boost Medicines Access, Affordability 16/02/2017 by William New, Intellectual Property Watch 1 Comment Once considered a breakthrough in negotiations to address problems of making cutting-edge medical products and research available to poor countries, the decade-old World Health Organization Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPOA) is now undergoing review, with the WHO Executive Board calling for a report on the initiative and plans for its future next year.